One of the truly revolutionary advances in hematopoietic cell transplantation (HCT) is the increasingly successful use of alternative donors, thereby allowing the delivery of a potentially curative transplant to B75% of patients who do not have an HLA-matched sibling donor. A substantial proportion of the need has been met by HLA-matched volunteer unrelated donors, but an unmet need still exists, particularly among minority populations and for people who need a more immediate source of hematopoietic cells. Two such sources, umbilical cord blood (UCB) and haploidentical related donors, have filled most of this need, and outcomes following transplants from these donor sources are very promising. UCB has the advantages of ready availability and is less capable of causing GVHD but hematological recovery and immune reconstitution are slow. Haploidentical HCT is characterized by the nearly uniform and immediate availability of a donor and the availability of the donor for post transplant cellular immunotherapy, but is complicated by a high risk of GVHD and poor immune reconstitution when GVHD is prevented by vigorous ex vivo or in vivo T-cell depletion. This review will discuss the pertinent issues that affect the choice of one donor source over another and offer recommendations regarding the optimal utilization of these donor sources. Bone Marrow Transplantation (2011) 46, 323-329; doi:10.1038/bmt.2010; published online 1 November 2010 Keywords: haploidentical transplant; cord blood transplant; alternative donors; GVHD
Introduction
Only 30% of patients have a matched sibling donor, and therefore the majority of patients who need an allogeneic transplant will need to find alternative hematopoietic cell sources. The National Marrow Donor Program and its cooperative international registries boast an estimated 12 million volunteer donors. It is estimated that B60% of Caucasian patients will be able to find a suitably matched unrelated donor and proceed to transplant. The outlook is worse for African-American patients and other minorities -African Americans represent 12% of the US population, but only 5% of unrelated transplants. Therefore, an estimated 5000 patients yearly are candidates for either a mismatched related donor (haploidentical), umbilical cord blood (UCB) or mismatched unrelated donor transplant. This review will focus on adults, and the advantages and disadvantages of the haploidentical and UCB approaches.
Haploidentical and UCB hematopoietic cell transplants (HCTs) have never been compared in a randomized fashion. In general, haploidentical HCTs are cheaper and easier to schedule, but may be associated with a higher risk of graft failure and GVHD. UCB, especially use of double UCB rather than single UCB units, are expensive and have a high risk of infection; however, the risk of severe GVHD is low. There may be some subgroups of patients (based on disease, match, and so on) who might be better served by one graft source over another. In this paper, we will review the clinical outcome data for each approach, and present two illustrative cases from our own institution.
Case presentation: cord blood transplant
A 69-year-old woman with a history of breast cancer, treated with surgery and radiation treatments, remains in continuous CR after therapy. After 5 years, she developed acute myelogeneous leukemia (therapy-related myeloid neoplasm) with normal cytogenetics, and was treated with idarubicin and cytarabine. She achieved CR and received consolidation therapy with cytarabine.
After 2 years, she relapsed and was treated on a clinical trial of cytarabine ± clofarabine. She entered into second CR. No matched sibling or unrelated donor was identified.
The patient was entered onto the BMT CTN (Blood and Marrow Transplant Clinical Trial Network) trial 0604 of reduced-intensity conditioning (RIC) and double UCB transplant. Per protocol, she received conditioning with fludarabine, CY and 200 cGy TBI. She was transplanted with two 4/6 matched UCB units with cell doses of 3.8 Â 10 7 NC/kg and 0.88 Â 10 5 CD34 þ cells/kg. GVHD prophylaxis was cyclosporine and mycophenolate mofetil.
Neutrophil engraftment occurred on day 17. Her post transplant course has been complicated by CMV reactivation, grade II cutaneous GVHD and pulmonary embolism thought to be related to inactivity. She is now 1-year post transplant and remains in continuous CR with an ECOG (Eastern Cooperative Oncology Group) performance status of 0.
Case presentation: haploidentical transplant
The patient is a 67-year-old female with blastoid variant mantle cell lymphoma, who achieved a CR with a modified Nordic regimen (R-CHOP alternating with riituximab/ cytarabine), then a consolidative first remission autologous HCT in June 2009. Recurrent disease was documented in October 2009 and she subsequently achieved a second CR following salvage chemotherapy with rituximab, gemcitabine and oxaliplatin. UCB and haploidentical HCT options were considered and she chose to be enrolled on the BMT CTN haploidentical HCT trial 0603. On 1 June 2010, following preparative therapy with CY, fludarabine and low-dose TBI, she received an HLA 3/6 matched HCT from her sister. CD34 þ cell dose was 3.98 Â 10 6 /kg. Neutrophil engraftment occurred on day 16 post transplant. Her post transplant course has been complicated by grade I cutaneous GVHD treated with topical corticosteroids and CMV reactivation treated with ganciclovir. She remains in remission B3 months post transplant.
These cases are presented to highlight the dilemmas that clinicians face when considering the myriad of transplant options for patients who do not have HLA-matched donors. Given the expanding boundaries of eligibility of HCT, and the improving outcomes following these alternative donor transplants, many patients who would previously not have been considered for alternative donor transplantation are now being successfully transplanted.
UCB transplantation
Single myeloablative UCB transplants The first successful UCB transplant was performed in 1988 in a child with Fanconi's anemia. Over the past 22 years, over 10 000 UCB transplants have been performed and over 400 000 UCB units have been donated and stored for unrelated transplant use. The early results in adults were somewhat disappointing, with a 40% TRM and a 26% disease-free survival. 1 More recent results, particularly from a multicenter investigation in Japan, have been encouraging, with a 5-year disease-free survival of 60-70% in patients with acute leukemia. 2, 3 The small size and genetic homogeneity of the population, and patient selection issues, may contribute to the success of the Japanese approach, as UCB has become a preferred stem cell source, preferred over fully matched unrelated donors in some cases. However, several European centers have also reported encouraging results with the single myeloablative approach; Sanz et al. 4 treated 49 adults with a thiotepa, BU and CY regimen, with a 2-year leukemia-free survival of 42% for all patients, and 75% for those patients transplanted in first CR.
Recently, Eapen et al. 5 compared 165 recipients of single myeloablative cord blood transplants with 888 recipients of unrelated peripheral blood stem cell transplants and 472 recipients of unrelated BM. The TRM was higher for the cord blood recipients, but leukemia-free survival was comparable among the different donor groups, suggesting that modern results with cord blood transplant approach those seen with unrelated adult donors.
Single RIC cord blood transplants The median age of AML patients is 68 years; therefore, a majority of patients with AML are not candidates for a myeloablative transplant. Several investigators have analyzed the outcomes after a reduced-intensity regimen in an effort to offer potentially curative therapy without the high toxicity of a myeloablative regimen. Uchida et al. 6 transplanted 70 patients over age 55 (median age 61) years with a variety of fludarabine-containing conditioning regimens. Progression-free survival at 2 years was 23%, with the majority of deaths from infection.
Rocha et al., 7 reporting for the Eurocord group, analyzed 176 patients with hematological malignancies treated with a variety of RIC regimens (95% fludarabine based), followed by single UCB transplant. The median age was 45 years, younger than the Japanese study above. Disease-free survival was 41% at 1 year in patients with acute leukemia, and disease status at transplant was the most important factor for survival.
Double myeloablative conditioning UCB transplants
As several of the early studies in adult UCB transplant showed a survival advantage to patients infused with a higher cell dose, a natural extension was to study the use of two UCB units, given sequentially-the double UCB unit approach. The University of Minnesota pioneered this approach in 23 patients with high-risk malignancies treated with a myeloablative TBI-containing regimen followed by the infusion of two partially matched (X4/6 A, B, DR HLA match between patient and UCB units and between two UCB units) infused sequentially. 8 Although GVHD was a theoretical concern given the infusion of two mismatched grafts, the incidence of severe GVHD was low at 13% and disease-free survival at 1 year was 57%.
There are no prospective studies to compare single and double UCB transplants in the adult population, although there is an ongoing BMT CTN trial in pediatric UCB recipients. A retrospective analysis has shown an increased risk of GVHD and decreased relapse with the use of a double UCB transplant, perhaps because of an increased GVL effect. 9 
Double RIC UCB transplants
The double UCB transplant approach was quickly extended to reduced-intensity transplants. Brunstein et al. 10 treated 110 patients-93 with double UCB-with the RIC regimen of fludarabine, CY and single-fraction TBI. Disease-free survival at 3 years was 38%.
In Boston, we have employed the double UCB approach in almost all of our adult UCB transplants. Using the RIC regimen of fludarabine, melphalan and antithymocyte globulin, we transplanted 21 patients using standard GVHD prophylaxis of cyclosporine and mycophenolate mofetil. Disease-free survival was 67% at 1 year.
11
Subsequent studies with the use of sirolimus and tacrolimus for GVHD prophylaxis have shown a very low rate of grades II-IV acute GVHD (9%) and a 2-year OS of 53%. 12 Survival was improved in patients with more robust thymic regeneration; patients with higher T-cell receptor excision circle (TREC) levels had improved outcomes. 13 Future trends in cord blood transplantation Survival of adult UCB transplant patients has improved from 23% disease-free survival 15 years ago to 38% disease-free survival today.
14 Several strategies to improve outcomes are currently in clinical trials. They include refined techniques for cord blood selection, such as selecting cord blood units that are matched for the noninherited maternal allele; patients receiving these grafts have a similar survival to those patients receiving fully matched UCB units. 15, 16 Investigators from Italy have pioneered the injection of cord blood directly into the BM. 17 Finally, several centers are using expansion techniques in an attempt to improve engraftment and immune recovery. 18 Rebuttal to cord blood UCB transplantation is a well-established option for patients who do not have matched related or unrelated donors, with acceptable GVHD and favorable survival probabilities compared with better matched donor sources. The advantages and disadvantages of UCB and haploidentical transplant are outlined in Table 1 . UCB units are usually readily available once suitably matched units with adequate cell dose have been identified. Cord blood strategies have also improved the diversity of the donor pool. Delayed engraftment and slow immune reconstitution, however, remain formidable problems following UCB transplantation. Haploidentical related donors are almost always available, both for the donation of stem cells and for later cellular therapy, and are usually immediately available. Multiple donors are often available and consideration can be given to factors such as CMV serostatus and ABO compatibility, and family inheritance (see below) in optimizing donor selection. Following UCB transplantation, the donor is not available for future cellular therapy, and advances in transplantation outcomes are likely to depend on post transplant modulation of the cellular environment using adoptively transferred cell populations.
Haploidentical hematopoietic cell transplantation
Background and rationale HCT from haploidentical related donors is an alternative option for patients without a suitably HLA-matched related or unrelated donor. [19] [20] [21] The advantage of haploidentical HCT is both real and theoretical. The most obvious advantage of haploidentical HCT is the almost universal availability of a related donor who is at least haplotype identical to the patient in need of a transplant. Such donors are usually available quickly, and can serve as repeat donors in the event of engraftment failure, or as donors of lymphocytes in order to convert mixed chimerism to full donor hematopoiesis or to treat disease relapse. A more potent graft vs tumor effect is a theoretically attractive benefit of haploidentical HCT as well. Early preclinical animal models suggested a more potent GVHD effect when MHC barriers were transgressed. 22 This benefit has been difficult to prove clinically, as there are no prospective randomized trials evaluating the antitumor efficacy of haploidentical HCT compared with matched related or unrelated donor stem cell transplants. Surprisingly, a higher relapse probability was observed in a retrospective analysis of the outcomes of transplants from T cell-depleted related and unrelated donors, one Agmismatched donors and haploidentical related donors by Drobyski et al. 23 On the other hand, Burroughs et al.
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showed that relapse probabilities were lower following nonmyeloablative low-dose TBI-based haploidentical non-T cell-depleted SCT than HLA-matched related or unrelated donor HCT. Given the higher risk of GVHD following haploidentical HCT and the frequent need for aggressive immunosuppressive therapy to treat the GVHD, it is possible that much of the antitumor effect is abrogated by this potent immunosuppressive therapy. Finally, so far as the potential benefit of haploidentical HCT when compared with UCB transplantation is concerned, the availability of the donors allows the opportunity to manipulate the cellular environment, both of the graft and post transplant via adoptive cellular immunotherapy. A brief summary of the history of haploidentical HCT, the outcomes of several current haploidentical HCT strategies and factors that may optimize the selection of donors for haploidentical HCT is warranted. These factors should allow for a better understanding of the role of haploidentical HCT in comparison to UCB transplantation. It should be pointed out though that both haploidentical and the 'usual' UCB transplants involve donors who are not HLA matched. Immune reconstitution is thus not ideal in either case and strategies are underway to address this limitation.
Haploidentical HCT from a historical perspective Early attempts with haploidentical HCT were notable for high rates of severe (often hyperacute) GVHD and graft rejection. 25 Furthermore, increased early mortality rates, due to multiorgan failure, often as the result of an inflammatory cytokine response at the time of engraftment, and high rates of opportunistic infection plagued this approach. These drawbacks were striking illustrations of the immunological consequences of crossing HLA barriers for transplantation. 25 In a retrospective analysis of BMT outcomes, patients who received an HLA two or three Ag-mismatched transplant had uniformly poor outcomes. These results differ significantly when compared with patients who received an HLA one Ag-mismatched transplant in whom survival outcomes were comparable to patients who received an HLA-matched related donor transplant. These studies underscored the high-risk nature of haploidentical HCT, particularly those that involved a 41 Ag mismatch. 26 Because of these early poor outcomes, progress in the field of haploidentical HCT was slow, and few centers were willing to undertake these complicated procedures. Haploidentical HCT outcomes, however, have improved considerably over the past decade as a result of many advancements in GVHD prevention. [27] [28] [29] [30] [31] [32] These successful strategies had included ex vivo T-cell depletion of the hematopoietic cell graft and/or in vivo T-cell depletion using antithymocyte globulin, alemtuzamab, vigorous pharmacologic anti-GVHD therapy, or combinations have improved patient outcome. Finally, technological advances in supportive care, including potent antiviral and antifungal agents, and the ability to modulate the cellular environment post transplant via adoptive cellular immunotherapy, such as donor lymphocyte infusion, have resulted in making haploidentical HCT an attractive option for patients who are in need of an alternative donor transplant.
Modern haploidentical HCT approaches most commonly have involved three general strategies: (1) myeloablative conditioning with vigorous ex vivo T cell-depleted (usually via CD34 þ cell selection) or anergized high-dose PBPC transplantation; 28, 29, 32 (2) RIC with ex vivo and/or in vivo T-cell depletion, and post transplant pharmacoprophylaxis or post transplant CY; 27,39,31 (3) myeloablative conditioning with in vivo T-cell depletion, non ex vivo T cell-depleted HCT and post transplant GVHD pharmacoprophylaxis. 32 Haploidentical HCT outcomes Most published haploidentical HCT series have been small (with o100 patients) and have included patients with diverse diseases and remission states at the time of transplantation. Variability in patient populations, preparative strategies and GVHD prophylaxis have made it difficult to reach consensus about the optimal strategy for haploidentical HCT. Furthermore, there are insufficient data to adequately evaluate what the long-term survival probabilities are following haploidentical HCT. With these limitations in mind, analyses of three commonly employed strategies with larger numbers of patients are worthy of discussion and comparison with the outcomes of UCB transplantation. Aversa et al., 29 using a strategy of myeloablative TBI-based conditioning with antithymocyte globulin, and ex vivo T cell-depleted high-dose CD34 selected PBPCs, demonstrated that engraftment was reliably achieved (100 of 101 evaluable patients) with minimal GVHD (8 patients with Xgrade II acute GVHD and 5 of 71 evaluable patients with chronic GVHD).
Favorable 2-year EFS probabilities of 48 and 46% were observed for patients with AML and ALL in remission. 29 For patients not in remission at the time of their transplant, distinctly inferior disease-free and OS probabilities were realized. A non-relapse mortality risk of 38%, principally because of opportunistic infection, demonstrated the highrisk nature of this strategy and the need for interventions to improve immune reconstitution post transplant. This promising approach has not been well reproduced at other centers, however, possibly reflecting differences in patient selection or supportive care.
RIC haploidentical HCT approaches have consisted primarily of various combination chemotherapy regimens with alemtuzamab or anti-thymocyte globulin for in vivo T-cell depletion, with promising early outcomes in small pilot clinical trials. Depletion of alloreactive T cells by highdose post transplant CY has been studied by investigators at Johns Hopkins Medical Center, and this strategy is now being evaluated in the multicenter BMT CTN study 0603. In a recent report on the outcomes of patients with hematological malignancies who received a haploidentical HCT with this strategy, a 35% EFS probability was observed among patients with a variety of myeloid and lymphoid malignancies. 31 The incidences of grade 2-4 acute GVHD and chronic GVHD were 31 and 15%, respectively. In a trial from Peking University, 250 patients with acute leukemia were treated with a BU-based myeloablative preparative regimen with antithymocyte globulin and triple drug (cyclosporine, MTX and mycophenolate mofetil) post transplant GVHD pharmacoprophylaxis. 32 Incidences of grade 2-4 acute and chronic GVHD were 45.8 and 53.9%, respectively. The 3-year leukemia-free survival probability for AML was 70.7% and for ALL 59.7%.
Thus, survival outcomes of haploidentical HCT have improved markedly over the past decade and success has been achieved with both myeloablative conditioning and RIC approaches with or without ex vivo T-cell depletion; however, these approaches almost always utilize either in vivo T-cell depletion or high-dose CY to deplete alloreactive T cells along with some form of post transplant GVHD pharmacoprophylaxis. Even the larger series, however, included diverse patient populations in terms of multiple diagnoses and remission statuses at the time of transplant. Not unexpectedly, survival probabilities were encouraging among patients with favorable risk disease and in remission at the time of the transplant, and abysmal in patients who were not in remission at the time of their transplant.
Optimizing donor selection
Emerging data have suggested that several donor-related factors may influence the outcome of haploidentical HCT. Of these variables, killer Ig-like receptor ligand mismatching in the GVH direction may be important in maximizing a graft vs tumor effect. 33, 34 This result has been most pronounced following myeloablative ex vivo T cell-depleted HCT for AML, 33 in which natural killer cells likely have a more important role in the antitumor effect of the transplant in the absence of T cells, but has also been demonstrated following nonmyeloablative T cell-replete HCT. 34 In the Perugia experience, no difference in relapse probability was seen for ALL following killer Ig-like receptor ligand-mismatched transplants.
Transplant outcomes following haploidentical HCT have also been influenced by the haplotype inheritance. 35, 36 In a large Center for International BMT Registry (CIBMTR) analysis, the incidence of acute GVHD was significantly lower following transplants from a noninherited maternal Ag-mismatched sibling donor than from a noninherited paternal Ag-mismatched sibling donor. 35 TRM was also found to be higher following transplants from a maternal or a paternal donor compared with transplants from a noninherited maternal Ag-mismatched sibling. In this analysis as well as a retrospective analysis by Ruggeri and colleagues, transplant outcomes were more favorable when a maternal rather than a paternal donor was used. 36 The principal of these apparent advantages, as well as the potential advantage of using UCB units that are matched for the noninherited maternal Ag, is that in utero leukocyte trafficking may lead to the development of long-lasting feto-maternal microchimerism and specific transplantation tolerance. Identification of donor-specific antibodies (DSAs) by a sensitive solid phase/single-Ag assay has been shown to correlate with a high risk of graft rejection; therefore, donors ideally should be chosen in whom donorspecific antibodies are not present. 37 
Future directions
Exciting opportunities exist to modulate the cellular environment created by haploidentical HCT. One strategy includes manipulating the graft (for example, by adding ex vivo-expanded MSCs). 38 Another approach is to modify the post transplant cellular environment by adoptive cellular immunotherapy using selected donor cell populations (for example, CD8-depleted lymphocyte infusions, selectively allodepleted T cells or NK cells) [39] [40] [41] . These efforts hopefully will provide more potent and more selective effector cell populations to optimize the antitumor effect of the transplant while avoiding the immunological consequences of crossing an HLA barrier, namely GVHD and graft rejection. In order to fully capitalize on the strategies that affect post transplant cellular reconstitution, the availability of the donor for future cell collections is paramount.
Haploidentical HCT compared with umbilical cord transplantation: concluding remarks Based on the existing data, it is not possible to make a convincing argument for the superiority of either haploidentical HCT or UCB transplantation for the treatment of hematological malignancies. Both haploidentical and the 'usual' UCB transplants involve donors who are not HLA matched, and hence immune reconstitution is not ideal. Our approach to donor selection at Massachusetts General Hospital is outlined in Figure 1 . No prospective randomized trial has been conducted to answer this question, and comparisons with historical control groups are limited by patient selection differences and, in many situations, small numbers of patients. No consensus has been reached on the optimal strategy for performing haploidentical HCT, and going forward, innovative strategies to modulate the cellular environment post transplant likely will lead to improvements in outcome compared with previously published data. Event-or leukemia-free survival probabilities for patients with AML and ALL in remission of 48 to 70.7% and 46 to 59%, respectively, in two of the larger haploidentical HCT trials, 29, 32 as discussed above, are encouraging. Furthermore, in a retrospective, multicenter analysis from the European Blood and Marrow Transplant Group, 42 leukemia-free survival probabilities of 48 and 21% for patients with AML in first CR, or second or later remission, appear to be comparable to the best results of UCB transplantation. For that matter, these results approach those obtained with matched related or unrelated donor SCT. Haploidentical HCT is therefore an appropriate treatment option for many patients who lack an HLA-matched related or unrelated donor.
Given the uncertainties of the role of haploidentical HCT in the treatment of hematological malignancies and other life-threatening blood dyscrasias, efforts should be made to encourage enrollment on clinical trials exploring novel strategies for optimizing immune reconstitution post transplant, and the graft vs tumor effect of the transplant. Prospective, randomized trials comparing haploidentical HCT to UBC transplantation and transplantation from other donor sources are warranted. For patients who are not enrolled on clinical trials, factors to consider in optimizing transplant outcomes should include: age of the patient, disease status (with, for example, younger patients with AML in remission likely benefiting from myeloablative ex vivo T cell-depleted transplants for AML) and donor selection (with preference given to killer Ig-like receptor ligand mismatching in the GVH direction, at least cord blood donor selection. An algorithm reflecting the approach at the Massachusetts General Hospital to selecting donor sources for patients who do not have an HLA-matched sibling. The choice of UCB or haploidentical HCT has been determined in part by the available protocol (which dictated specific inclusion criteria), or when a protocol was not available by prior experience with certain diseases (for example, a lack of success with RIC haploidentical HCT approaches for patients with myeloid malignancies).
in AML, and noninherited maternal Ag-mismatched sibling donors, when available). Another important consideration when choosing the hematopoietic progenitor cell donor source for transplant is the urgency of the transplant, with haploidentical related donors generally being available in a faster time frame, as well as being available for subsequent cellular collections should the need for adoptive cellular immunotherapy arise.
Rebuttal of haploidentical transplant
Haploidentical transplants offer the advantage of ready availability, but the GVHD associated with this approach has been severe in several American and European studies. T-cell depletion has been used to decrease the incidence of GVHD, but has also been associated with a higher risk of relapsed disease. The use of post transplant CY is intriguing, but there is a concern over engraftment delay. Thus, the data on haploidentical transplants are not as robust as UCB transplants. A randomized study comparing these two alternative donor sources would be timely.
